Antonio Francavilla, Thomas E. Starzl, Michele Barone, Qi‐Hua Zeng, Kendrick A. Porter, Adrianni Zeevi, Peter M. Markus, Marcell R. M. van den Brink, Satoru Todo – 1 July 1991 – Evidence could not be found of immune modulation of liver regeneration. The powerful immunosuppressive drug FK 506, which augments the response after partial hepatectomy in normal rats, had the same effect in T cell—deficient nude rats. The cytotoxicity of natural killer cells in treated nude rats was not significantly changed by FK 506 therapy.

Yashushi Yamaguchi, William G. M. Hardison – 1 July 1991 – During a recent study using isolated perfused rat liver, we concluded that the effects of vasopressin on biliary excretion of several anionic and cationic cholephilic probes could best be explained by passive diffusion of these probes through a paracellular pathway with permeability increased by vasopressin.

1 July 1991

Lori A. Bottalico, Hannah T. Betensky, Young B. Min, Shelley B. Weinstock – 1 July 1991 – One drawback to using perfluorochemical emulsions as blood substitutes is that perfluorochemical particles are cleared from the blood by the reticuloendothelial system, primarily liver and spleen. We measured the impact of two perfluorochemical emulsions on clearance of colloidal carbon (< 1 μm) and 51Cr‐sheep red blood cells (about 8 μm) by the reticuloendothelial system in vivo and in the isolated perfused liver.

Ned Ballatori – 1 July 1991 – The liver is the major organ which eliminates leukotriene C4 (LTC4) and other cysteinyl leukotrienes from the blood circulation into bile. Transport of LTC4 was studied using inside‐out vesicles enriched in canalicular and sinusoidal membranes from rat liver. The incubation of canalicular membrane vesicles with [3H]LTC4 in the presence of ATP resulted in an uptake of LTC4 into vesicles. The initial rate of ATP‐stimulated LTC4 uptake was about 40‐fold higher in canalicular than in sinusoidal membrane vesicles.

Telfer B. Reynolds – 1 July 1991 – In a double‐blind randomized trial, the hemodynamic events following the administration of propranolol (n = 51) or a placebo (n = 51) were prospectively studied in cirrhotic patients with esophageal varices. The hepatic venous pressure gradient, heart rate, and variceal size were determined at the baseline and 3, 12, and 24 months after the beginning of therapy. Baseline values were similar in both groups.

Pei‐Jer Chen, Meei‐Hua Lin, Su‐Jen Tu, Ding‐Shinn Chen – 1 July 1991 – To clone and characterize hepatitis C virus strains present in Taiwan, RNA was extracted from liver tissue collected from a patient during the acute phase of posttransfusion non‐A, non‐B hepatitis. RNA was then subjected to complementary DNA synthesis and the polymerase chain reaction, using primers derived from the original nucleotide sequence of the United States hepatitis C virus strain.

Corinne Vons, Jean‐Paul Pegorier, Jean Girard, Claude Kohl, Marie‐Agnès Ivanov, Dominique Franco – 1 June 1991 – The effects of pancreatic hormones and cyclic AMP on long‐chain fatty‐acid metabolism were investigated in human hepatocytes isolated from 12 liver biopsy specimens and cultured for 4 days in an insulin‐free medium. Glucagon (10−6 mol/L) increased endogenous ketone body production by 150%. This resulted from alterations in the partition of long‐chain fatty acids from esterification toward oxidation.

Domenico Alvaro, Mario Angelico, Alfredo Cantafora, Eugenio Gaudio, Claudia Gandin, Maria Teresa Santini, Roberta Masella, Livo Capocaccia – 1 June 1991 – The intravenous administration of dimethylethanolamine in the rat promotes a selective enrichment of liver membranes with polyunsaturated phosphatidylcholines. The effect of dimethylethanolamine pretreatment on cholestasis induced by estradiol 17β‐D‐glucuronide, a potent cholestatic agent, was assessed in this study. Dimethylethanolamine, dissolved in sodium‐taurocholate was infused intravenously (0.3 mg/kg/min) for 15 hr.

Mercedes Ruiz‐Moreno, Maria José Rua, Josefina Molina, Gloria Moraleda, Alberto Moreno, Jaime García‐aguado, Vicente Carréño – 1 June 1991 – Thirty‐six children with chronic hepatitis B were entered into a randomized controlled trial of recombinant human interferon‐α All patients had hepatitis B virus DNA and increased levels of aminotransferases in serum for at least 1 yr. Twelve children received 10 MU of interferon‐α 2b/m2 body surface area three times a week (group I); 12 children received 5 MU/m2 under the same conditions (group II); and 12 children served as controls (group III).